Company / Shareholders' Equity
Anixa Biosciences Inc Shareholders' Equity History
FY2014-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$20.0M
FY2024
5-year range
$5.2M / $29.0M
FY2020-FY2024
Trend
-17.8%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has fluctuated over the past 10 years, ranging from -$3M in FY2014 to $29M in FY2022.
Based on SEC 10-K filings.
$20M in FY2024 with a 5-year CAGR of +30.7%.
Declined from $29M to $20M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +30.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +30.7%, indicating consistent growth.
- In FY2024, shareholders' equity decreased 17.8% year-over-year.
- Peak shareholders' equity was recorded in FY2022.
- Lowest shareholders' equity in the period was in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.53 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $20.0M | -17.8% |
| FY2023 | $24.3M | -16.2% |
| FY2022 | $29.0M | +231.5% |
| FY2020 | $8.8M | +67.3% |
| FY2019 | $5.2M | -3.7% |
| FY2018 | $5.4M | -31.4% |
| FY2017 | $7.9M | +56.8% |
| FY2016 | $5.1M | +26.0% |
| FY2015 | $4.0M | +220.7% |
| FY2014 | -$3.3M | -413.8% |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026